• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

On a mis­sion to save Te­va from crip­pling debt, Schultz stands by cost-cut­ting mea­sures, scru­ti­nizes per prod­uct ...

8 years ago
R&D
Pharma

Af­ter bumpy 2017, Cel­gene CEO says tak­ing risk is the on­ly way for­ward

8 years ago
Pharma

Shire cre­ates sep­a­rate neu­ro­sciences di­vi­sion for fu­ture in­vest­ments; Agenus gains $28M in roy­al­ty deal

8 years ago
News Briefing

Sanofi, Re­gen­eron up the ante on PD-1 I/O pro­gram by a bil­lion dol­lars

8 years ago
R&D
Pharma

Te­va inks $200M glob­al li­cens­ing deal with mi­graine ri­val Alder

8 years ago
R&D
Pharma

Ax­o­vant shares blast­ed as Vivek Ra­maswamy's pre­mier drug proves worth­less, sec­ond drug miss­es key goal

8 years ago
R&D

No­vo Nordisk tries to tack­le Abl­ynx and bring it in­to the fold with a $3B buy­out of­fer, but the biotech keeps say­ing ...

8 years ago
Deals

Al­ny­lam kicks off #JPM18 with a re­struc­tured Sanofi deal, grab­bing glob­al rights to patisir­an

8 years ago
Pharma

De­vel­op­ing a Sanofi cast-off, Im­pact Bio­med­i­cines now sub­ject of $7B Cel­gene ac­qui­si­tion deal

8 years ago
Deals

Pfiz­er is ax­ing its neu­ro­sciences di­vi­sion, lay­ing off 300 and dis­card­ing new drugs

8 years ago
R&D
Pharma

Af­ter re­sist­ing a push to the auc­tion block, Acor­da preps for a sale and shares shoot up — re­port

8 years ago
Deals

J&J does Alzheimer's gene ther­a­py deal, along with 14 oth­er new col­lab­o­ra­tions

8 years ago
Cell/Gene Tx

Sanuj Ravin­dran to lead Pelle­Pharm as CEO; Paul Hast­ings leaves On­coMed; Mod­er­na taps John Mendlein as pres­i­dent

8 years ago
Peer Review

Lund­beck part­ners with Van­der­bilt on new schiz­o­phre­nia drug; Pere­grine of­fi­cial­ly re­named Avid BioSer­vices in pur­suit ...

8 years ago
News Briefing

Kala Phar­ma shares dam­aged by mixed da­ta from PhI­II dry eye pro­gram

8 years ago
R&D

Chi­na's KBP Bio is com­ing to Amer­i­ca, with $76M A round and GSK vet tak­ing the helm in Philly

8 years ago
Financing
China

Neu­rode­gen­er­a­tion star De­nali nabs a cash-rich, $1B-plus Alzheimer’s part­ner­ship with Take­da

8 years ago
Pharma

Take­da swoops in to buy stem cell part­ner TiGenix for $630M, putting it on the thresh­old of a like­ly ap­proval

8 years ago
Deals

Fa­heem Has­nain and his ex-Re­cep­tos team launch a new biotech with $100M and a twist on the old biotech mod­el

8 years ago
Financing
Startups

SVB's crys­tal ball points to big mon­ey biotech IPOs, down­shift in the tor­rid pace of ven­ture in­vest­ing

8 years ago
Financing
Deals

INC Re­search and in­Ven­tiv Health come un­der Sy­neos Health brand in clos­ing chap­ter of CRO merg­er

8 years ago
Deals
Outsourcing

Biotech in­vestapalooza con­tin­ues with more ven­ture rounds for star­tups; Ova­Science cuts half of its work­force (again)

8 years ago
News Briefing

On a roll, Macro­Gen­ics al­lies with Roche on a bis­pe­cif­ic de­vel­op­ment cam­paign

8 years ago
R&D
Pharma

At­las builds its dream team and hands over $25M to launch a new ap­proach to gene ther­a­py

8 years ago
Startups
Cell/Gene Tx
First page Previous page 1067106810691070107110721073 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Confirm Profile

Endpoints News